Lexaria Bioscience Announces Tolerability And Additional Pharmacokinetic Results From Human Pilot Study #2, GLP-1-H24-2, Have Been Received; DehydraTECH-processed Rybelsus Capsules Demonstrated Superior Tolerability In Delivering The GLP-1 Drug Semaglutide Versus Commercially Available Rybelsus
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience announced positive results from its human pilot study, showing that DehydraTECH-processed Rybelsus capsules have superior tolerability compared to commercially available Rybelsus tablets. The study found no adverse events in participants taking the DehydraTECH capsules, while those taking the standard tablets experienced mild adverse events.
August 29, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience's DehydraTECH-processed Rybelsus capsules demonstrated superior tolerability in a recent study, with no adverse events reported, unlike the commercially available Rybelsus tablets.
The study results highlight the effectiveness and safety of Lexaria's DehydraTECH technology, which could lead to increased interest and potential market share for Lexaria's products. This positive news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100